Drugs / [18F]DK222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07140315 | Jul 2026 → Jul 2027 expected | non-small cell lung carcinoma, urothelial carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]DK222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07140315 ↗ |
| Modality | Diagnostic / imaging agent | “investigational radiotracer used detect non-small cell lung cancer (NSCLC) or Urothelial Cancer (UC) tissue in the body when used with positron emission tomography/computed tomography” NCT07140315 ↗ |
| Route | Intravenous | “injected into the participant's vein an intravenous line” NCT07140315 ↗ |